Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results, Beats Expectations By $0.02 EPS

Autolus Therapeutics (NASDAQ:AUTL) released its quarterly earnings data on Thursday. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02, Zacks reports. Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.The business had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• Q1 revenue came in at $26.2 million, up sharply from $9.0 million a year ago, and management reiterated full-year 2026 revenue guidance of $120 million to $135 million.
• The company reported its first positive gross margin for AUCATZYL in the quarter, supported by higher volume and manufacturing/operational improvements, with margins expected to keep improving through 2026.
• Autolus said U.S. and U.K. launch momentum is building, with 73 U.S. centers active and more than 10 centers already live in the U.K.; management expects U.S. centers to exceed 80 by year-end.
• The company’s real-world data continue to support obe-cel’s profile, citing no high-grade CRS, 3% high-grade ICANS, and more than 90% overall response rate, while noting patient use is expanding into older and more complex populations.
• Management highlighted a broad pipeline for obe-cel, including pediatric ALL, lupus, lupus nephritis, progressive MS, and AL amyloidosis, with several data readouts expected in late 2026 through 2028.

Autolus Therapeutics Trading Down 7.0%

Shares of AUTL opened at $1.59 on Friday. The firm’s 50 day moving average is $1.48 and its 200-day moving average is $1.51. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.70. The stock has a market capitalization of $423.16 million, a PE ratio of -1.47 and a beta of 1.93.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AUTL. UBS Group AG raised its position in Autolus Therapeutics by 16.1% during the third quarter. UBS Group AG now owns 410,662 shares of the company’s stock valued at $669,000 after purchasing an additional 56,995 shares in the last quarter. Millennium Management LLC bought a new position in Autolus Therapeutics in the third quarter valued at about $639,000. Tudor Investment Corp ET AL boosted its position in Autolus Therapeutics by 36.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 282,113 shares of the company’s stock worth $561,000 after buying an additional 75,460 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Autolus Therapeutics by 90.5% during the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock worth $375,000 after purchasing an additional 78,058 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of Autolus Therapeutics by 17.3% in the 3rd quarter. Two Sigma Investments LP now owns 172,143 shares of the company’s stock valued at $281,000 after buying an additional 25,346 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AUTL has been the topic of several recent analyst reports. HC Wainwright lifted their price objective on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Finally, Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.